Extracorporeal Photopheresis-An Overview

Area of Science:

• Immunomodulation
• Photopheresis
• Cellular Therapy

Background:

• Extracorporeal photopheresis (ECP) has been FDA-approved for Sézary Syndrome, a CTCL variant, since 1988.
• ECP has demonstrated efficacy in graft-vs.-host disease (GVHD), scleroderma, and solid organ transplantation.
• The precise mechanism of ECP remains under investigation, evolving from direct apoptosis induction to immune cell modulation.

Purpose of the Study:

• To review the established and emerging applications of ECP in various clinical settings.
• To elucidate the evolving understanding of ECP's mechanism of action.
• To provide recommendations for optimizing ECP use and guide future research.

Main Methods:

• Literature review of ECP applications and mechanisms.
• Analysis of clinical evidence for ECP in CTCL, GVHD, and transplantation.
• Discussion of current ECP guidelines and future research directions.

Main Results:

• ECP is a first-line treatment for Sézary Syndrome and a second-line option for refractory mycosis fungoides.
• ECP shows promise as a second-line therapy for steroid-refractory acute and chronic GVHD.
• ECP may enhance tissue tolerance and reduce infections in solid organ transplantation, though CMV remains a concern.

Conclusions:

• ECP is an established therapy for CTCL and GVHD, with expanding applications.
• Understanding ECP's immunomodulatory effects is crucial for optimizing its use.
• Prospective randomized trials are needed to further define ECP's role and improve patient outcomes.